Evidence map›Paper›PMID 42749751›Full record

ReviewCommunications biology2026

Reverse bioengineering of the liver: developmental principles for next-generation liver-on-a-chip systems.

Ken-Ichiro Kamei

Abstract readReview
In one paragraph

Review in Communications biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Ken-Ichiro KameiProgram of Biology, Division of Science, New York University Abu Dhabi, Abu Dhabi, United Arab Emirates. kamei.kenichiro.7r@kyoto-u.ac.jp.ORCID 0000-0003-2948-3264

Funding

New York University Abu Dhabi AD366
6 · The paper itself

Abstract

Despite major advances in liver-on-a-chip and organoid technologies, most current in vitro liver models remain limited. Here, it is argued that these limitations are fundamentally conceptual rather than purely technical. Reverse bioengineering is introduced as a unifying design framework for liver-on-a-chip systems, in which human liver development is treated as the primary engineering blueprint rather than adult hepatic phenotype as the endpoint. Existing cell sources, liver organoids, and liver-on-a-chip platforms are critically evaluated, demonstrating that each capture complementary but incomplete aspects of liver development. Pluripotent stem cells uniquely enable access to intrinsic developmental programs and cellular diversity, organoids partially reconstruct early developmental trajectories through self-organization, and microphysiological systems provide extrinsic cues without fully encoding developmental execution. Finally, futured directions are outlined, highlighting developmentally coordinated multi-organ systems, quantitative developmental benchmarks, and the emerging role of multi-omics-enabled Digital Twins and artificial intelligence in guiding and interpreting liver-on-a-chip design.

Indexed as

BioengineeringLab-On-A-Chip DevicesLiverTissue EngineeringAnimalsHumansMicrophysiological SystemsOrganoidsPluripotent Stem Cells

Identifiers

PMID42749751
PMCPMC13582956

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.